IPO Mechanics and Strategy: Debt Down, Growth Up
According to a Tuesday filing, the proceeds from the IPO will primarily be used to repay existing debt under NIQ’s revolving credit facility and U.S. term loan, while any remaining funds will support working capital and general corporate initiatives.
The offering also includes a 30-day option for underwriters to scoop up an additional 7.5 million shares at the IPO price—adding a layer of momentum to what’s already a turbocharged debut.
Heavy Hitters in the Legal Arena
The IPO was steered by a high-powered legal team from Ropes & Gray LLP, including partners across capital markets, tax, cybersecurity, and private equity sectors. On the flip side, underwriters were advised by Simpson Thacher & Bartlett LLP, with partner Richard Fenyes leading the charge.
This deal isn’t just about capital—it’s a chess match of regulatory navigation, corporate structure, and private equity muscle.
A Rising IPO Tide: Carlsmed Joins the Fray
NIQ wasn’t the only headline-maker. Carlsmed Inc., a medtech company specializing in spinal surgery solutions, also made its public debut Wednesday, raising $100.5 million on Nasdaq by selling 6.7 million shares at $15 apiece. Represented by Morrison Foerster LLP, with underwriters advised by Latham & Watkins LLP, Carlsmed’s IPO adds to a resurging market wave.
